Firmagon - (80 mg/vial and 120 mg/vial; Powder, Subcutaneous)

Generic Name	Degarelix	**Innovator**	Ferring
Dosage	80 mg/vial and 120 mg/vial; Powder, Subcutaneous	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	None	**Generic Launches**	None
Indication	FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.